Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,521 across all filing types
Latest filing 2022-03-22 Notice of Dividend Amou…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Notice of Dividend Amount Classification · 95% confidence The document is titled 'ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021' and contains detailed information about a final dividend declaration, including dividend amount, payment dates, ex-dividend date, record date, and shareholder approval date. It also includes information about the share registrar and directors. The document length is 3318 characters, which is relatively short and primarily focuses on dividend details rather than full financial statements or comprehensive annual results. There is no substantive financial data or analysis presented, only the dividend announcement details. According to the MENU VS MEAL RULE, such a document is best classified as a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release. Therefore, the appropriate classification is DIV with high confidence.
2022-03-22 English
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report Classification · 100% confidence The document is titled 'ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021' and contains detailed financial highlights, including revenue, profit, earnings per share, and dividend information for the full fiscal year 2021. It includes a Chairman's Statement, Business Review, Industry Review, Outlook, and Management Discussion and Analysis sections. The content is comprehensive and covers the company's full-year financial performance and strategic outlook, typical of an Annual Report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-22 English
VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG JMT103 MEETS PRE-DEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIAL FOR THE TREATMENT OF UNRESECTABLE OR SURGICALLY DIFFICULT GIANT CELL TUMOR OF BONE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial results of a new drug JMT103. It provides detailed information about the clinical trials, efficacy, and future marketing application plans. The document is an announcement of a significant development related to the company's product pipeline, not a financial report, regulatory filing, or meeting material. It does not contain financial statements, voting results, or management changes. It is a corporate announcement about a product development milestone, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-03-21 English
VOLUNTARY ANNOUNCEMENT - "DUVELISIB CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a product called 'Duvelisib Capsules'. It contains no financial data, no regulatory form references, no fiscal period information, and no detailed financial or operational report content. The length is 4135 characters, which is relatively short and typical for an announcement. The content focuses on a product approval and clinical trial updates, which is a corporate announcement rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-03-18 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2021
Regulatory Filings Classification · 85% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the year ended 31 December 2021. It references the subsidiary's Annual Report published on the Shenzhen Stock Exchange website and provides extracted financial data such as revenue, net profit, earnings per share, and asset changes. The document is titled as an "INSIDE INFORMATION" announcement and includes detailed financial figures and analysis, not merely a notice of report publication. The content includes substantive financial data and analysis for a full fiscal year, consistent with an Annual Report or a summary thereof. However, since it is an announcement of principal financial information extracted from the subsidiary's Annual Report rather than the full Annual Report itself, and it is published as an announcement on the Hong Kong Stock Exchange, it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement disclosing financial information but not the full Annual Report of the parent company. The document length (7106 characters) and detailed financial data exclude it from being a mere Report Publication Announcement (RPA). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-03-17 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the annual results for the year ended 31 December 2021 and to consider the payment of a final dividend. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and its agenda. The document length is only 1292 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement about a report (annual results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2022-03-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.